Conclusion: These data confirm increased expression of IDO under hypoxic and inflammatory conditions, both of which are present within the diseased kidney environment. Blocking studies using the IDO inhibitor 1-MT are underway to determine LEE011 in vitro the functional role of IDO in PTEC immune-modulation. It is anticipated that results
from these experiments will help elucidate the mechanistic pathways of PTEC immune-modulation and may provide insights for novel therapy in the treatment of inflammatory kidney disease. 172 INTRARENAL INNERVATION IN HYPERTENSIVE AND DIABETIC RODENTS P DAVERN, K JANDELEIT-DAHM, G HEAD, A WATSON Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia Aim: To assess differences in intrarenal nerves in hypertensive and normotensive rodents with and without concomitant diabetes. Background: Hypertensive diabetic patients have increased renal sympathetic nerve activity and develop nephropathy at an accelerated rate however little is known of changes in renal sympathetic innervation in either hypertension or diabetes. Methods: Studies were carried out in hypertensive and diabetic rodents to assess differences in intrarenal innervation. Twenty-three week old hypertensive (BPH/2J) and normotensive (BPN/3J)
Schlager mice were killed and perfused with normal saline, cold 4% PFA and kidneys embedded in paraffin. Streptozotocin induced diabetic C57Bl6 and apolipoprotein E knockout (apoE KO) mice were killed after 20 weeks of diabetes and kidneys
fixed in 10% NBF before PFT�� datasheet being embedded in paraffin. Streptozotocin induced diabetic spontaneously hypertensive rats (SHRs) were killed after 32 weeks of diabetes and kidneys were similarly fixed and embedded. All kidneys were cut and stained with the neural marker tyrosine hydroxlyase (TH). Results: There was more staining for TH in cortical tubules of hypertensive mice compared with normotensive controls (26 ± 2% vs 19% ± 1% respectively, n = 4/group, P < 0.05). Diabetic C57Bl6 and apoE KO mice appeared to have a redistribution of staining with a greater staining intensity in the distal convoluted tubules. This pattern of staining was also seen in diabetic SHRs compared to non-diabetic SHRs. Conclusions: These results indicate that intrarenal innervation Masitinib (AB1010) is altered in the hypertensive and also the diabetic kidney, suggesting changes in the neural control of the kidney in such conditions. This has direct implications for the treatment of hypertension and renal disease, especially for renal nerve ablation. 173 DENOSUMAB CAUSES SEVERE HYPOCALCAEMIA AND HUNGRY BONE SYNDROME IN PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE V DAVE, C CHIANG, J BOOTH, P MOUNT Austin Health, Victoria, Australia Aim: To study the risk of hypocalcaemia with denosumab in patients with stage IV and stage V chronic kidney disease (CKD).